Skip to content
Screener

Tarsus Pharmaceuticals, Inc. TARS Business Segments — Sales & Marketing

Similar metrics at other companies

Veracyte logo
VCYTReportable Segment — Sales & Marketing
$27.16M+11.0%
Celsius Holdings, Inc. logo
CELHReportable Segment — Sales & Marketing
$181.9M+20.6%
SANUWAVE Health, Inc. logo
SNWVReportable Segment — Sales & Marketing
$1.92M+14.9%
MiMedx Group logo
MDXGReportable Segment — Sales & Marketing
$46.42M-3.0%
Porch Group, Inc. logo
PRCHReportable Segment — Sales & Marketing
$410K+28.1%
Vericel logo
VCELSingle Reportable Segment — Sales & Marketing
$28.46M+27.6%

Other financials

Income statement

See full
Revenue$173.9M+69.4%
Gross profit$161.8M+67.8%
Operating income-$19.9M+10.3%
Net income-$18.6M+8.8%
EPS (diluted)-$0.43+10.4%

Balance sheet

See full
Cash & equivalents$206.6M+108%
Total debt$88.8M+22.6%
Total equity$346.7M+4.2%
Total assets$611.1M+23.5%

Cash flow

See full
Operating cash flow$61.2M+308%
CapEx$4.1M+306%
Free cash flow$57.2M+288%

Valuation

See full
Market cap$2.84B+34.5%
Enterprise value$2.73B+30.6%
P/S4.7×-2.5×

Profitability

See full
Gross margin79.8%
Operating margin-8%-3.5pp
Net margin-7.7%-3.3pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-13.7%-4.9pp
Debt / equity0.3×0.0×
Current ratio3.2×-2.1×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.

The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:25 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001819790-26-000064
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Operating expenses:
Cost of sales12,1136,23721,50911,448
Research and development31,01015,59453,36130,003
Selling and marketing90,00265,857174,484126,143
General and administrative60,69537,156112,64261,865
Total operating expenses193,820124,844361,996229,459
Loss from operations(19,908)(22,184)(26,030)(48,464)
Other reconciling items(1)1,3571,8445123,004

Item 1. Financial Statements

FAQ

What is Tarsus Pharmaceuticals, Inc.'s business segments — sales & marketing?
Tarsus Pharmaceuticals, Inc. (TARS) reported business segments — sales & marketing of $90M in Q2 2026.
How has Tarsus Pharmaceuticals, Inc.'s business segments — sales & marketing changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s business segments — sales & marketing increased by 36.7% year-over-year, from $65.86M to $90M.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s business segments — sales & marketing?
Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s business segments — sales & marketing has grown at a 134.0% compound annual growth rate (CAGR), from $20.89M to $267.68M.
What does business segments — sales & marketing mean?
Reflects the costs associated with promoting, advertising, and distributing the company's commercial products to healthcare providers and patients. This is a critical indicator of the company's commercial scaling efforts and market penetration strategy.

Ask your AI about Tarsus Pharmaceuticals, Inc.'s business segments — sales & marketing.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude